The Journal of Pain
Volume 11, Issue 4 , Pages 360-368 , April 2010

Impact of Postherpetic Neuralgia and Painful Diabetic Peripheral Neuropathy on Health Care Costs

  • Robert H. Dworkin

      Affiliations

    • Departments of Anesthesiology and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York
    • Corresponding Author InformationAddress reprint requests to Dr Robert H. Dworkin, Department of Anesthesiology, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Box 604, Rochester, NY 14642.
    • ,
  • Daniel C. Malone

      Affiliations

    • University of Arizona, Tucson, Arizona and Strategic Therapeutics, LLC, Tucson, Arizona
    • ,
  • Christopher J. Panarites

      Affiliations

    • NeurogesX, Inc, San Mateo, California
    • ,
  • Edward P. Armstrong

      Affiliations

    • University of Arizona, Tucson, Arizona and Strategic Therapeutics, LLC, Tucson, Arizona
    • ,
  • Sissi V. Pham

      Affiliations

    • Sissi Pham Consulting, Inc, Chapel Hill, North Carolina

Received 3 April 2009 ,Revised 17 July 2009 ,Accepted 8 August 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by grants from NeurogesX, Inc, to the University of Rochester Office of Continuing Professional Education, IMS Health Inc (formerly Health Benchmarks, Inc), Strategic Therapeutics, and Sissi Pham Consulting, Inc. Dr Dworkin has received research support, consulting fees, or honoraria in the past year from Allergan, Alpharma, Arcion, Astellas, AstraZeneca, BioLineRx, Boehringer Ingelheim, Cara, Cervelo, Durect, Eisai, Endo, Forest, Genzyme, Grünenthal, Johnson & Johnson, KAI Pharmaceuticals, Lilly, Merck, NeurogesX, Neuromed, Nuvo, Ono, Pfizer, Philips Respironics, Sanofi Aventis, Solace, UCB Pharma, US Department of Veterans Affairs, US National Institutes of Health, Wyeth, Xenon, and XTL Biopharmaceuticals and is a Special Government Employee of the US Food and Drug Administration Center for Drug Evaluation and Research; Drs Malone and Armstrong have received consulting fees in the past year from NeurogesX through Strategic Therapeutics; Dr Panarites owns shares of Covance, Johnson & Johnson, and Sanofi-Aventis and is an employee of NeurogesX; and Dr Pham owns shares of Glaxo SmithKline and in the past year has received consulting fees from Bristol-Myers Squibb, General Electric, NeurogesX, and Zelos.

PII: S1526-5900(09)00693-2

doi: 10.1016/j.jpain.2009.08.005

The Journal of Pain
Volume 11, Issue 4 , Pages 360-368 , April 2010

Article Tools

* Image Usage & Resolution